![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication August 2, 2004.
Revised September 2, 2004.
Accepted for publication September 3, 2004.
The recent discovery of nonsteroidal selective androgen receptor modulators (SARMs) provides a promising alternative for testosterone replacement therapies, including hormonal male contraception. The identification of an orally bioavailable SARM with the ability to mimic the central and peripheral androgenic and anabolic effects of testosterone would represent an important step toward the "male pill". We characterized the in vitro and in vivo pharmacologic activity of (S)-3-(4-Chloro-3-fluorophenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)propionamide ( C-6), a novel SARM developed in our laboratories. C-6 was identified as an androgen receptor (AR) agonist with high AR binding affinity (Ki = 4.9 nM). C-6 showed tissue-selective pharmacologic activity with higher anabolic activity than androgenic activity in male rats. The dose required to maintain the weight of the prostate, seminal vesicles, and levator ani muscle to one-half of the size of the maximum effects (i.e., ED50) was 0.78 ± 0.06, 0.88 ± 0.1 and 0.17 ± 0.04 mg/day, respectively. As opposed to other SARMs, gonadotropin levels in C-6-treated groups were significantly lower than control values. C-6 also significantly decreased serum testosterone concentration in intact rats after two weeks treatment. Marked suppression of spermatogenesis was observed after 10 weeks treatment with C-6 in intact male rats. Pharmacokinetic studies of C-6 in male rats revealed that C-6 was well absorbed after oral administration (bioavailability 76%), with a long (6.3 h) half-life at a dose of 10 mg/kg. These studies show that C-6 mimicked the in vivo pharmacologic and endocrine effects of testosterone while maintaining the oral bioavailability and tissue-selective actions of nonsteroidal SARMs.
Key words:
SARM, androgen, androgen receptor, male contraception, nonsteroidal ligand, spermatogenesis
This article has been cited by other articles:
|
|
 |
|
  A. Jones, J. Chen, D. J. Hwang, D. D. Miller, and J. T. Dalton Preclinical Characterization of a (S)-N-(4-Cyano-3-Trifluoromethyl-Phenyl)-3-(3-Fluoro, 4-Chlorophenoxy)-2-Hydroxy-2-Methyl-Propanamide: A Selective Androgen Receptor Modulator for Hormonal Male Contraception Endocrinology, January 1, 2009; 150(1): 385 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Page, J. K. Amory, and W. J. Bremner Advances in Male Contraception Endocr. Rev., June 1, 2008; 29(4): 465 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, K. C. Ahn, N. A. Gee, M. I. Ahmed, A. J. Duleba, L. Zhao, S. J. Gee, B. D. Hammock, and B. L. Lasley Triclocarban Enhances Testosterone Action: A New Type of Endocrine Disruptor? Endocrinology, March 1, 2008; 149(3): 1173 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ostrowski, J. E. Kuhns, J. A. Lupisella, M. C. Manfredi, B. C. Beehler, S. R. Krystek Jr., Y. Bi, C. Sun, R. Seethala, R. Golla, et al. Pharmacological and X-Ray Structural Characterization of a Novel Selective Androgen Receptor Modulator: Potent Hyperanabolic Stimulation of Skeletal Muscle with Hypostimulation of Prostate in Rats Endocrinology, January 1, 2007; 148(1): 4 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wu, Z. Wu, J. Yang, V. A. Nair, D. D. Miller, and J. T. Dalton PHARMACOKINETICS AND METABOLISM OF A SELECTIVE ANDROGEN RECEPTOR MODULATOR IN RATS: IMPLICATION OF MOLECULAR PROPERTIES AND INTENSIVE METABOLIC PROFILE TO INVESTIGATE IDEAL PHARMACOKINETIC CHARACTERISTICS OF A PROPANAMIDE IN PRECLINICAL STUDY Drug Metab. Dispos., March 1, 2006; 34(3): 483 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, D. J. Hwang, K. Chung, C. E. Bohl, S. J. Fisher, D. D. Miller, and J. T. Dalton In Vitro and in Vivo Structure-Activity Relationships of Novel Androgen Receptor Ligands with Multiple Substituents in the B-Ring Endocrinology, December 1, 2005; 146(12): 5444 - 5454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chen, J. Kim, and J. T. Dalton Discovery and Therapeutic Promise of Selective Androgen Receptor Modulators Mol. Interv., June 1, 2005; 5(3): 173 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Bohl, W. Gao, D. D. Miller, C. E. Bell, and J. T. Dalton Structural basis for antagonism and resistance of bicalutamide in prostate cancer PNAS, April 26, 2005; 102(17): 6201 - 6206. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
